223 related articles for article (PubMed ID: 36343054)
1. Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis.
Xian F; Wu C; Zhang G; Xu G
Medicine (Baltimore); 2022 Nov; 101(44):e31479. PubMed ID: 36343054
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
3. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
4. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S
BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Yang TK; Yu YF; Tsai CL; Li HJ; Yang PS; Huang KW; Cheng JC
BMC Cancer; 2022 Oct; 22(1):1085. PubMed ID: 36271374
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
9. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis.
Lei Q; Yan X; Zou H; Jiang Y; Lai Y; Ung COL; Hu H
Discov Oncol; 2022 Sep; 13(1):95. PubMed ID: 36171533
[TBL] [Abstract][Full Text] [Related]
11. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
[TBL] [Abstract][Full Text] [Related]
12. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
13. Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
Ning C; Zhang X; Wang Y; Yang X; Yang X; Chao J; Xun Z; Xue J; Wang Y; Sun H; Li Y; Zhang N; Zhu C; Hou X; Sang X; Zhao H
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1461-1471. PubMed ID: 37433375
[TBL] [Abstract][Full Text] [Related]
14. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study.
Yao J; Zhu X; Wu Z; Wei Q; Cai Y; Zheng Y; Hu X; Hu H; Zhang X; Pan H; Zhong X; Han W
Cancer Med; 2022 Oct; 11(19):3612-3622. PubMed ID: 35403359
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
Li X; Ding X; Li W; Chen J
Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
[TBL] [Abstract][Full Text] [Related]
17. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy.
Pradeep J; Win TT; Aye SN; Sreeramareddy CT
J Cancer; 2022; 13(10):3091-3102. PubMed ID: 36046644
[No Abstract] [Full Text] [Related]
20. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
